State Street Health Care Select Sector SPDR ETF (XLV) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.65: the stock has moved about 35% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerState Street Health Care Select Sector SPDR ETF (XLV) trades at $165.66. The State Street Health Care Select Sector SPDR ETF (XLV) mirrors the Health Care Select Sector Index, offering targeted exposure to the U.S. healthcare industry. Sector: Financial services.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for XLV: XLV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XLV against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
State Street Health Care Select Sector SPDR ETF (XLV) Financial Services Profile
State Street Health Care Select Sector SPDR ETF (XLV) provides investors with focused exposure to the health care sector of the S&P 500, tracking companies in pharmaceuticals, biotechnology, and healthcare services. With a market cap of $39.58 billion, it offers a strategic tool for targeted investment in the U.S. healthcare market.
What Is the Investment Thesis for XLV?
The State Street Health Care Select Sector SPDR ETF (XLV) presents a targeted investment vehicle for those seeking exposure to the U.S. healthcare sector. With a beta of 0.65, it demonstrates lower volatility compared to the broader market. The fund's focus on pharmaceuticals, biotechnology, and healthcare services positions it to benefit from long-term trends such as an aging population and advancements in medical technology. However, regulatory changes and potential drug pricing pressures represent ongoing risks. The ETF's performance is directly tied to the performance of the Health Care Select Sector Index, making it crucial to monitor the overall health and outlook of the U.S. healthcare industry.
Based on FMP financials and quantitative analysis
XLV Key Highlights
Market Cap of $39.58 billion, reflecting its significant presence in the asset management space.
- Beta of 0.65, indicating lower volatility compared to the broader market, potentially offering a more stable investment.
- Exposure to the Health Care Select Sector Index, providing targeted access to the U.S. healthcare sector.
- Holdings include companies in pharmaceuticals, biotechnology, and healthcare services, diversifying exposure within the healthcare industry.
- Managed by State Street Global Advisors, a reputable asset management firm with extensive experience in ETFs.
Who Are XLV's Competitors?
XLV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| DFAC Dimensional U.S. Core Equity 2 ETF | $44.84 | -0.60% | $47.8B | — |
| DGRO iShares Core Dividend Growth ETF | $78.37 | +0.76% | $41.3B | — |
| DIA SPDR Dow Jones Industrial Average ETF Trust | $520.80 | -0.62% | $43.8B | — |
| SCHB Schwab U.S. Broad Market ETF | $29.23 | -0.58% | $44.1B | — |
| SMH VanEck Semiconductor ETF | $560.28 | -2.44% | $70.6B | — |
| BX Blackstone Inc. | $129.75 | +3.46% | $157B | 705-pillar |
| IVSXF Investor AB (publ) | $42.20 | 0.00% | $129B | 599-signal |
| BAM Brookfield Asset Management | $47.24 | -1.01% | $75.4B | 575-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are XLV's Key Strengths?
Targeted exposure to the U.S. healthcare sector.
- Diversification across multiple healthcare industries.
- Low expense ratio compared to actively managed funds.
- Managed by a reputable asset management firm.
What Are XLV's Weaknesses?
Concentration in a single sector, increasing risk.
- Vulnerability to regulatory changes in the healthcare industry.
- Dependence on the performance of the Health Care Select Sector Index.
- No dividend yield.
What Could Drive XLV Stock Higher?
XLV catalyst: Potential for new drug approvals and therapies to boost performance of pharmaceutical and biotechnology companies within the ETF.
- Aging population driving increased demand for healthcare services and products.
- Technological advancements in medical devices and healthcare technology improving patient outcomes and driving industry growth.
What Are the Key Risks for XLV?
Regulatory changes and drug pricing pressures impacting profitability of pharmaceutical companies.
- Economic downturns reducing healthcare spending and impacting demand for healthcare services.
- Competition from other healthcare-focused ETFs and investment vehicles.
- Dependence on the performance of the Health Care Select Sector Index, which may be affected by broader market trends.
What Are the Growth Opportunities for XLV?
- Aging Population: The global population is aging, leading to increased demand for healthcare services and products. This demographic shift is expected to drive growth in the healthcare sector, benefiting companies held within the XLV ETF. As the elderly population grows, the demand for pharmaceuticals, medical devices, and healthcare services will likely increase, creating a favorable environment for the ETF's holdings. The United Nations projects that the number of people aged 60 years or over will double by 2050, creating a significant long-term growth opportunity.
- Technological Advancements: Rapid advancements in medical technology, such as gene therapy, robotic surgery, and artificial intelligence, are transforming the healthcare industry. Companies developing and implementing these technologies are poised for growth, potentially boosting the performance of the XLV ETF.
- Emerging Markets: As emerging markets experience economic growth, healthcare spending is expected to increase, creating new opportunities for healthcare companies. The XLV ETF, with its exposure to leading healthcare companies, may benefit from this trend. The growing middle class in emerging markets is driving demand for better healthcare services and access to advanced medical treatments, leading to increased investment in the healthcare sector.
- Drug Development: The pharmaceutical and biotechnology industries are constantly developing new drugs and therapies to treat a wide range of diseases. Successful drug development can lead to significant revenue growth for companies, positively impacting the XLV ETF.
- Healthcare Reform: Changes in healthcare policy and regulations can create both opportunities and challenges for the healthcare industry. However, reforms aimed at expanding access to healthcare and improving quality of care could benefit companies within the XLV ETF. For example, policies that encourage the use of generic drugs or promote preventive care could lead to increased demand for certain healthcare products and services.
What Are XLV's Competitive Advantages?
- Established Brand: State Street is a well-known and respected asset manager with a long history of providing investment solutions.
- Index Tracking: The ETF's performance is tied to a well-established index, providing transparency and predictability.
- Scale: The ETF's large asset base allows it to operate efficiently and offer competitive expense ratios.
What Does XLV Do?
The State Street Health Care Select Sector SPDR ETF (XLV) was created to replicate, before fees and expenses, the price and yield performance of the Health Care Select Sector Index. This index is designed to represent the healthcare sector within the broader S&P 500, offering investors a way to concentrate their investments in this specific area of the market. XLV provides exposure to a range of healthcare-related industries, including pharmaceuticals, healthcare equipment and supplies, healthcare providers and services, biotechnology, life sciences tools and services, and healthcare technology. By focusing on these specific segments, XLV allows investors to take strategic or tactical positions in the healthcare sector, offering a more targeted approach compared to broader market investments. The ETF's holdings are weighted by market capitalization, meaning that larger companies within the index have a greater impact on its overall performance. XLV is managed by State Street Global Advisors, a well-established asset management firm with a long history of providing investment solutions to a wide range of clients. The ETF is based in Boston, USA, and is designed to provide precise exposure to the U.S. healthcare market.
What Products and Services Does XLV Offer?
- Tracks the performance of the Health Care Select Sector Index.
- Provides exposure to companies in the pharmaceuticals industry.
- Offers access to companies in the biotechnology industry.
- Includes companies in the healthcare equipment and supplies industry.
- Invests in companies in the healthcare providers and services industry.
- Covers companies in the life sciences tools and services industry.
- Targets companies in the healthcare technology industry.
How Does XLV Make Money?
- The ETF generates revenue through management fees charged to investors.
- The fund's performance is directly linked to the performance of the underlying Health Care Select Sector Index.
- State Street Global Advisors manages the ETF and is responsible for its investment strategy and operations.
What Industry Does XLV Operate In?
The asset management industry is characterized by a diverse range of investment products, including ETFs, mutual funds, and hedge funds. The State Street Health Care Select Sector SPDR ETF (XLV) operates within this industry by offering a specialized investment product focused on the healthcare sector. The ETF competes with other healthcare-focused funds and broader market ETFs. The healthcare sector itself is influenced by factors such as demographic trends, technological advancements, and regulatory changes. As the population ages and demand for healthcare services increases, ETFs like XLV may benefit from increased investor interest.
Who Are XLV's Key Customers?
- Institutional investors seeking targeted exposure to the U.S. healthcare sector.
- Retail investors looking for a convenient way to invest in a diversified portfolio of healthcare stocks.
- Financial advisors using ETFs as part of their clients' investment portfolios.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 49 |
| 2026-08-26 | 49 |
| 2026-08-29 | 49 |
| 2026-09-01 | 49 |
| 2026-09-04 | 49 |
| 2026-09-07 | 49 |
| 2026-09-10 | 49 |
What changed?
The score has stayed at 49.
Over the same 18 days the stock moved -5.0%.
XLV Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the U.S. healthcare sector.
- Diversification across multiple healthcare industries.
- Low expense ratio compared to actively managed funds.
- Managed by a reputable asset management firm.
Bear Case
- Concentration in a single sector, increasing risk.
- Vulnerability to regulatory changes in the healthcare industry.
- Dependence on the performance of the Health Care Select Sector Index.
- No dividend yield.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
XLV Latest News
-
Sector Update: Healthcare Stocks Ease in Afternoon Trading
MT Newswires · Sep 11, 2026
-
S&P 500 Snaps 4-Day Decline as Oil Cools, Dell Jumps 11%: Stock Market Today
benzinga · Sep 11, 2026
-
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Inflation Data Release
MT Newswires · Sep 11, 2026
-
Leading And Lagging Sectors For September 11, 2026
benzinga · Sep 11, 2026
XLV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for XLV.
Price Targets
Wall Street price target analysis for XLV.
XLV MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for XLV; grades run from A+ (80-100) to F (below 30).
Latest News
Sector Update: Healthcare Stocks Ease in Afternoon Trading
S&P 500 Snaps 4-Day Decline as Oil Cools, Dell Jumps 11%: Stock Market Today
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Inflation Data Release
Leading And Lagging Sectors For September 11, 2026
Latest State Street Health Care Select Sector SPDR ETF Analysis
XLV Financial Services Stock FAQ
Is XLV a good stock?
Stock Expert AI does not rate XLV buy, sell or hold. State Street Health Care Select Sector SPDR ETF has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does State Street Health Care Select Sector SPDR ETF do?
The State Street Health Care Select Sector SPDR ETF (XLV) is designed to track the performance of the Health Care Select Sector Index, providing investors with targeted exposure to the U.S. healthcare sector.
What are the key factors to evaluate for XLV?
Evaluate XLV on fundamentals, analyst consensus, and risk factors. The State Street Health Care Select Sector SPDR ETF (XLV) presents a targeted investment vehicle for those seeking exposure to the U.S. healthcare sector. Not financial advice.
How frequently does XLV data refresh on this page?
XLV's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven XLV's recent stock price performance?
State Street Health Care Select Sector SPDR ETF (XLV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to the U. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XLV overvalued or undervalued right now?
State Street Health Care Select Sector SPDR ETF (XLV) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of XLV?
Yes, most major brokerages offer fractional shares of State Street Health Care Select Sector SPDR ETF (XLV) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track XLV's earnings and financial reports?
State Street Health Care Select Sector SPDR ETF (XLV) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for XLV earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The ETF's performance is dependent on the performance of the Health Care Select Sector Index.
- Regulatory changes in the healthcare industry can significantly impact the ETF's performance.